The threat of drug-resistant bacteria continues to grow — and so does our commitment to helping you combat this global issue. As a leader in diagnostics for more than 50 years, we have made it our mission to innovate and advocate for better antibiotic stewardship.
Discover how Roche can help you bring insights and innovative solutions to your institution’s antibiotic stewardship program.
*AMR mortality projection compared to leading causes of death worldwide in 2014
Antibiotics are an important treatment option, but their misuse is causing devastating impact.
Substantial investments in numerous assays that help clinicians make more effective treatment decisions using antibiotics or antivirals
Educational support for healthcare providers so they can successfully comply with new regulatory mandates
A deep-seated commitment to promote and implement principles of good antibiotic stewardship
Learn about Global AMR Challenge
Treat common infections with confidence at the earliest possible convenience.
This CLIA-waived system is uniquely positioned to provide accurate, actionable results at the point of care. Whether results are positive or negative, you can confidently treat patients without the need to wait for confirmation.
The Elecsys BRAHMS PCT solution aids in assessing the mortality risk of patients fighting sepsis and guiding antibiotic decision-making for patients with lower respiratory tract infections, like pneumonia, bronchitis, COPD and sepsis.8,9
Identify and contain healthcare-associated infections (HAIs).
The cobas MRSA/SA and Cdiff tests provide provide excellent performance and broad coverage to increase confidence in HAI testing. Run on the fully automated cobas 4800 system, these assays may help your institution control infections and costs.
Roche is your partner in building a successful antibiotic stewardship program that’s designed to:
References
1 The Review on Antimicrobial Resistance. “Tackling Drug-Resistant Infections Globally: Final Report and Recommendations.” May 2016, https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf (accessed September 25, 2017).
2 Centers for Disease Control and Prevention. “1 in 3 antibiotic prescriptions unnecessary.” CDC Newsroom. https://www.cdc.gov/media/releases/2016/p0503-unnecessary-prescriptions.html (accessed February 6, 2018).
3 Centers for Disease Control and Prevention. “The Core Elements of Hospital Antibiotic Stewardship Programs.” https://www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html (accessed February 6, 2018).
4 Magill SS, O'Leary E, Janelle SJ, et al. Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals. N Engl J Med 2018; 379:1732-1744. https://www.nejm.org/doi/full/10.1056/NEJMoa1801550. Accessed November 12, 2018..
5 National Quality Forum. “National Quality Partners Playbook: Antibiotic Stewardship in Acute Care.” http://www.qualityforum.org/Publications/2016/05/National_Quality_Partners_Playbook__Antibiotic_Stewardship_in_Acute_Care.aspx (accessed February 6, 2018).
6 Hansen, Glen T., Johanna Moore, Emily Herding, Tami Gooch, Diane Hirigoyen, Kevan Hanson and Marcia Deike. (2018). Clinical decision making in the emergency department setting using rapid PCR: Results of the CLADE study group. Journal of Clinical Virology 102:42–49.
7 Peppard, W.J. and N.A. Ledeboer. (2014). Implementation of Polymerase Chain Reaction to Rule Out Clostridium Difficile Infection is Associated with Reduced Empiric Antibiotic Duration of Therapy. Hospital Pharmacy 49(7):639–643.
8 Elecsys BRAHMS PCT [package insert]. Indianapolis, IN: Roche Diagnostics; 2016.
9 Elecsys BRAHMS PCT antibiotic initiation and deescalation claims are pending 510(k) clearance.
10 Broyles, Michael R. (October 3, 2017). “Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real-world Evidence.” Open Forum Infectious Diseases. Volume 4, Issue 4, ofx213. https://doi.org/10.1093/ofid/ofx213 (accessed July 24, 2018).
COBAS, LIAT and ELECSYS are trademarks of Roche.
© 2018 Roche Diagnostics, North America. All rights reserved.
